The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.
With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.
The NCI will launch a lab network to provide researchers with centralized assays for conducting genomic and pharmacodynamic analysis for molecularly targeted drugs.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.
